|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Effect of grapefruit juice on the pharmacokinetics of tolvaptan, a non-peptide arginine vasopres- sin antagonist, in healthy subjects 显示文摘 | Shoaf SE Mallikaarjun S Bricmont P | 2012 | Eur J Clin Pharmacol2012，68，2： | 1 |
| 2 | Pharmacokinetics,pharmacodynamics,and safety of tolvaptan,a nonpeptide AVP antagonist,during ascending single-dose studies in healthy subjects显示文摘 | Shoaf SE Wang Z Bricmont P | 2007 | J Clin Pharmacol2007，47，12： | 1 |
| 3 | Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects显示文摘 | Shoaf SE Wang Z Bricmoont P | 2007 | J Clin Pharmacolo2007，47，12： | 1 |
| 4 | Rapid changes in cytochrome P4502E 1 (CYP2E 1)activity and other P450 isoenzymes follow ethanol withdrawal in rats显示文摘 | Roberts BJ Shoaf SE Song BJ | 1995 | Biochem Pharmacol1995，49，11： | 1 |
| 5 | Effect of grapefruit juice on the pharmacokinetics of tolvaptan, a non-peptide arginine vasopressin antagonist,in healthy subjects显示文摘 | Shoaf SE Mallikaarjun S Bricmont P | 2012 | Eur J Clin Pharmacol2012，68，2： | 1 |
| 6 | Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy sub- jects显示文摘 | Shoaf SE | 2007 | J Clin Pharmacol2007，47，： | 1 |
| 7 | Effect of grapefruit juice on the pharmacokinetics of tolvaptan, a non-peptide arginine vasopressin antagonist,in healthy subjects显示文摘 | Shoaf SE Mallikaarjun S Briemont P | 2012 | Eur J Clin Pharmacol2012，68，2： | 1 |
| 8 | The pharmacokinetics of S-(-) Equol administered as SE5-OH tablets to healthy postmenopausal women显示文摘 | Setchell KD Zhao X Shoaf SE | 2009 | J Nutr2009，139，11： | 1 |
| 9 | Rapid changes in cytochrome P4502E1 (CYP2E1)activity and other P450 isozymes following ethanol withdrawal in rats 显示文摘 | Roberts BJ Shoaf SE Song BJ | 1995 | Biochem Pharmacol1995，49，11： | 1 |
| 10 | Pharmacoki- netics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending sin- gle-dose studies in healthy subjects显示文摘 | Shoaf SE Wang Z Bricmont P | 2007 | J Clin Phar- maeol2007，47，12： | 1 |
| 11 | Pharmocokine- ties, pharmaeodynamies, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects显示文摘 | SHOAF SE WANG Z BRICMONT P | 2007 | J Clin Pharmacol2007，47，12： | 1 |
| 12 | Pharmoco- kinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochloro- thiazide显示文摘 | SHOAF SE BRAMER SL BRICMONT P | 2007 | J Cardiovasc Pharmacol2007，50，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员